Silence Therapeutics Plc ( (SLN) ) has released its Q1 earnings. Here is a breakdown of the information Silence Therapeutics Plc presented to its investors.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Silence Therapeutics is a global clinical-stage biotechnology company focused on developing precision-engineered siRNA therapies to target and silence disease-associated genes, particularly in the liver, addressing high unmet medical needs in cardiovascular, hematology, and rare diseases. In its first-quarter 2025 earnings report, Silence Therapeutics highlighted its strong clinical and operational execution, particularly in advancing the SANRECO Phase 2 study of divesiran for Polycythemia Vera (PV), and maintaining a robust financial position with over $136 million in cash and equivalents. Key financial metrics revealed a net loss of $28.5 million, driven by increased R&D and G&A expenses, as the company continues to invest in its proprietary mRNAi GOLD platform and clinical programs. Strategic advancements include progressing Phase 3 readiness activities for Zerlasiran in cardiovascular disease and ongoing collaborations, such as the SLN312 study with AstraZeneca. Looking forward, Silence Therapeutics remains committed to enhancing stakeholder value through prudent investments and cost-saving initiatives, extending its cash runway into 2028 while focusing on its core programs.